ArticleEuropean urology open science2026
Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adjuvant nivolumab has shown efficacy in randomized trials for high-risk urothelial carcinoma after radical surgery, but its real-world outcomes remain unclear. Objective: To evaluate the association between adjuvant nivolumab and oncological outcomes in real-world practice. Design setting and participants: This retrospective, multicenter study analyzed 366 patients with high-risk bladder cancer or upper tract urothelial carcinoma who underwent radical surgery between 2016 and 2025 at 18 institutions in the Japanese AGEHA database. Patients were classified into an adjuvant nivolumab group ( Outcome measurements and statistical analysis: The primary analysis compared adjuvant nivolumab with observation alone using propensity score matching (PSM). Secondary analyses included PSM comparisons between adjuvant nivolumab, adjuvant chemotherapy, and exploratory subgroup analyses. Results: In the primary PSM cohort (97 matched pairs), adjuvant nivolumab was associated with improved disease-free survival (DFS; hazard ratio [HR] = 0.56, 95% confidence interval [CI] = 0.35-0.88) and overall survival (OS; HR = 0.40, 95% CI = 0.19-0.81) compared with observation alone. In secondary analyses, DFS and OS appeared similar between adjuvant nivolumab and adjuvant chemotherapy. Site-specific analyses demonstrated consistent benefits in patients with muscle-invasive bladder cancer, whereas adequate covariate balance could not be achieved for patients with upper tract urothelial carcinoma. Conclusions: In this multicenter real-world cohort, adjuvant nivolumab was associated with improved DFS and OS compared with observation after radical surgery; however, these findings require confirmation in future studies designed to minimize residual confounding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.